- Home
- COLL vs GILT Comparison
COLL vs GILT Comparison
Compare COLL & GILT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- GILT
- Stock Information
- Founded
- COLL 2002
- GILT 1987
- Country
- COLL United States
- GILT Israel
- Employees
- COLL N/A
- GILT N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- GILT Radio And Television Broadcasting And Communications Equipment
- Sector
- COLL Health Care
- GILT Technology
- Exchange
- COLL Nasdaq
- GILT Nasdaq
- Market Cap
- COLL 958.8M
- GILT 894.0M
- IPO Year
- COLL 2015
- GILT 1993
- Fundamental
- Price
- COLL $32.10
- GILT $13.64
- Analyst Decision
- COLL Strong Buy
- GILT Strong Buy
- Analyst Count
- COLL 4
- GILT 1
- Target Price
- COLL $44.25
- GILT $11.00
- AVG Volume (30 Days)
- COLL 354.8K
- GILT 1.1M
- Earning Date
- COLL 11-06-2025
- GILT 11-12-2025
- Dividend Yield
- COLL N/A
- GILT N/A
- EPS Growth
- COLL N/A
- GILT 12.49
- EPS
- COLL 1.06
- GILT 0.39
- Revenue
- COLL $707,007,000.00
- GILT $349,746,000.00
- Revenue This Year
- COLL $22.23
- GILT $47.18
- Revenue Next Year
- COLL $2.78
- GILT $13.80
- P/E Ratio
- COLL $31.21
- GILT $36.54
- Revenue Growth
- COLL 22.61
- GILT 19.67
- 52 Week Low
- COLL $23.23
- GILT $4.83
- 52 Week High
- COLL $39.95
- GILT $14.65
- Technical
- Relative Strength Index (RSI)
- COLL 30.71
- GILT 64.34
- Support Level
- COLL $34.19
- GILT $13.47
- Resistance Level
- COLL $35.83
- GILT $14.49
- Average True Range (ATR)
- COLL 1.05
- GILT 0.62
- MACD
- COLL -0.33
- GILT 0.04
- Stochastic Oscillator
- COLL 0.00
- GILT 66.46
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About GILT Gilat Satellite Networks Ltd.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.